Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Lipoprotein(a) as a cardiovascular risk factor: current status

BG. Nordestgaard, MJ. Chapman, K. Ray, J. Borén, F. Andreotti, GF. Watts, H. Ginsberg, P. Amarenco, A. Catapano, OS. Descamps, E. Fisher, PT. Kovanen, JA. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, MR. Taskinen, L. Tokgözoglu, A. Tybjærg-Hansen, . ,

. 2010 ; 31 (23) : 2844-53. [pub] 20101021

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu konsensus - konference, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027952

AIMS: The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp(a), on desirable levels, and on therapeutic strategies. METHODS AND RESULTS: The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/coronary heart disease (CHD) risk, together with recent genetic findings, indicates that elevated Lp(a), like elevated LDL-cholesterol, is causally related to premature CVD/CHD. The association is continuous without a threshold or dependence on LDL- or non-HDL-cholesterol levels. Mechanistically, elevated Lp(a) levels may either induce a prothrombotic/anti-fibrinolytic effect as apolipoprotein(a) resembles both plasminogen and plasmin but has no fibrinolytic activity, or may accelerate atherosclerosis because, like LDL, the Lp(a) particle is cholesterol-rich, or both. We advise that Lp(a) be measured once, using an isoform-insensitive assay, in subjects at intermediate or high CVD/CHD risk with premature CVD, familial hypercholesterolaemia, a family history of premature CVD and/or elevated Lp(a), recurrent CVD despite statin treatment, ≥3% 10-year risk of fatal CVD according to European guidelines, and/or ≥10% 10-year risk of fatal + non-fatal CHD according to US guidelines. As a secondary priority after LDL-cholesterol reduction, we recommend a desirable level for Lp(a) <80th percentile (less than ∼50 mg/dL). Treatment should primarily be niacin 1-3 g/day, as a meta-analysis of randomized, controlled intervention trials demonstrates reduced CVD by niacin treatment. In extreme cases, LDL-apheresis is efficacious in removing Lp(a). CONCLUSION: We recommend screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level <50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027952
003      
CZ-PrNML
005      
20121207100822.0
007      
ta
008      
120817e20101021enk f 000 0#eng||
009      
AR
024    7_
$a 10.1093/eurheartj/ehq386 $2 doi
035    __
$a (PubMed)20965889
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Nordestgaard, Børge G $u Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, DK-2730 Herlev, Denmark. brno@heh.regionh.dk
245    10
$a Lipoprotein(a) as a cardiovascular risk factor: current status / $c BG. Nordestgaard, MJ. Chapman, K. Ray, J. Borén, F. Andreotti, GF. Watts, H. Ginsberg, P. Amarenco, A. Catapano, OS. Descamps, E. Fisher, PT. Kovanen, JA. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, MR. Taskinen, L. Tokgözoglu, A. Tybjærg-Hansen, . ,
520    9_
$a AIMS: The aims of the study were, first, to critically evaluate lipoprotein(a) [Lp(a)] as a cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp(a), on desirable levels, and on therapeutic strategies. METHODS AND RESULTS: The robust and specific association between elevated Lp(a) levels and increased cardiovascular disease (CVD)/coronary heart disease (CHD) risk, together with recent genetic findings, indicates that elevated Lp(a), like elevated LDL-cholesterol, is causally related to premature CVD/CHD. The association is continuous without a threshold or dependence on LDL- or non-HDL-cholesterol levels. Mechanistically, elevated Lp(a) levels may either induce a prothrombotic/anti-fibrinolytic effect as apolipoprotein(a) resembles both plasminogen and plasmin but has no fibrinolytic activity, or may accelerate atherosclerosis because, like LDL, the Lp(a) particle is cholesterol-rich, or both. We advise that Lp(a) be measured once, using an isoform-insensitive assay, in subjects at intermediate or high CVD/CHD risk with premature CVD, familial hypercholesterolaemia, a family history of premature CVD and/or elevated Lp(a), recurrent CVD despite statin treatment, ≥3% 10-year risk of fatal CVD according to European guidelines, and/or ≥10% 10-year risk of fatal + non-fatal CHD according to US guidelines. As a secondary priority after LDL-cholesterol reduction, we recommend a desirable level for Lp(a) <80th percentile (less than ∼50 mg/dL). Treatment should primarily be niacin 1-3 g/day, as a meta-analysis of randomized, controlled intervention trials demonstrates reduced CVD by niacin treatment. In extreme cases, LDL-apheresis is efficacious in removing Lp(a). CONCLUSION: We recommend screening for elevated Lp(a) in those at intermediate or high CVD/CHD risk, a desirable level <50 mg/dL as a function of global cardiovascular risk, and use of niacin for Lp(a) and CVD/CHD risk reduction.
650    _2
$a věkové faktory $7 D000367
650    _2
$a zvířata $7 D000818
650    _2
$a kardiovaskulární nemoci $x krev $x genetika $x prevence a kontrola $7 D002318
650    _2
$a koronární nemoc $x krev $x genetika $x prevence a kontrola $7 D003327
650    _2
$a časná diagnóza $7 D042241
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hyperlipoproteinemie $x diagnóza $x genetika $x terapie $7 D006951
650    _2
$a imunoanalýza $x metody $7 D007118
650    _2
$a lipoprotein (a) $x krev $x genetika $7 D017270
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši transgenní $7 D008822
650    _2
$a výběr pacientů $7 D018579
650    _2
$a rizikové faktory $7 D012307
650    _2
$a sexuální faktory $7 D012737
655    _2
$a konsensus - konference $7 D016446
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chapman, M John
700    1_
$a Ray, Kausik
700    1_
$a Borén, Jan
700    1_
$a Andreotti, Felicita $7 gn_A_00006518
700    1_
$a Watts, Gerald F
700    1_
$a Ginsberg, Henry
700    1_
$a Amarenco, Pierre $7 gn_A_00005280
700    1_
$a Catapano, Alberico
700    1_
$a Descamps, Olivier S
700    1_
$a Fisher, Edward
700    1_
$a Kovanen, Petri T
700    1_
$a Kuivenhoven, Jan Albert
700    1_
$a Lesnik, Philippe
700    1_
$a Masana, Luis
700    1_
$a Reiner, Zeljko
700    1_
$a Taskinen, Marja-Riitta
700    1_
$a Tokgözoglu, Lale
700    1_
$a Tybjærg-Hansen, Anne
700    1_
$a ,
773    0_
$w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 31, č. 23 (20101021), s. 2844-53
856    41
$u https://pubmed.ncbi.nlm.nih.gov/20965889 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20121207100856 $b ABA008
999    __
$a ok $b bmc $g 949994 $s 785298
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 31 $c 23 $d 2844-53 $e 20101021 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
LZP    __
$a Pubmed-20120817/11/03

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...